Norestin5 mg

Norestin is a synthetic progestin used in the treatment of several gynecological conditions. Evidence-based uses include:

• Established/on-label uses: treatment of dysfunctional uterine bleeding (abnormal uterine bleeding not due to structural or malignant causes), secondary amenorrhea, endometriosis, and short-term postponement (delay) of menstruation for scheduling purposes.
• Guideline-supported use: management of menorrhagia (heavy menstrual bleeding) as part of an overall treatment plan.
• Combination-therapy role: Norestin is also used as the progestin component of combined oral contraceptives and in progestin-only contraceptive preparations.
• Adjunct use: some product labeling supports Norestin as an adjunct for premenstrual syndrome (PMS) symptom relief, although evidence is less robust than for its other indications.

Off-label, Norestin is sometimes used by physicians to manipulate the timing of the menstrual cycle around surgery, travel, or examinations; such use should only be under medical supervision.

Each Norethisterone tablet, as commonly marketed, contains Norethisterone (or its ester, norethisterone acetate) 5 mg as the active ingredient, together with pharmaceutically inert excipients such as lactose, starch, and magnesium stearate used in tablet manufacture. Norethisterone is also available internationally in a long-acting injectable ester form (norethisterone enanthate) used for contraception. The exact strength and excipients vary by brand, so the specific product label dispensed should always be checked.

Norestin is a synthetic progestogen (a 19-nortestosterone derivative) used in women's health for menstrual cycle disorders, endometriosis, and as a component of hormonal contraception. It works by mimicking the natural hormone progesterone, producing secretory changes in the endometrium and, at sufficient doses, inhibiting ovulation.

Norestin is most commonly administered orally as tablets; in some countries it is also available as a long-acting intramuscular injection. It has been used clinically for decades, both as a single-ingredient product and as part of fixed-dose combination contraceptive formulations.

Norestin belongs to the therapeutic class of Progestogens (synthetic progestins), a subgroup of female sex hormones used in gynecology and reproductive health.

Mechanism of Action

Norethisterone is a synthetic progestin derived from 19-nortestosterone. It binds to progesterone receptors in the endometrium, myometrium, and hypothalamic-pituitary axis, producing progesterone-like effects. It converts proliferative endometrium into secretory endometrium, helping to control abnormal uterine bleeding, and at sufficient doses suppresses gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH) release, inhibiting ovulation.

Pharmacokinetics

Norethisterone is well absorbed after oral administration and undergoes hepatic first-pass metabolism, with elimination chiefly via urine and feces. In addition to its progestogenic activity, it has some inherent androgenic and mild estrogenic activity due to its steroid structure.

Norestin tablets are taken by mouth, with or without food, at approximately the same time(s) each day to maintain steady hormone levels. If a dose is missed, it should be taken as soon as remembered; if it is almost time for the next dose, the missed dose should be skipped rather than doubled. Tablets should be swallowed whole with water. Always follow the cycle-day instructions given by the prescribing physician, since timing relative to the menstrual cycle affects the efficacy of Norestin.

CYP3A4 Enzyme Inducers

Drugs that induce hepatic CYP3A4 enzymes - including rifampicin, certain anticonvulsants (e.g., phenytoin, carbamazepine, barbiturates), and St. John's Wort - can accelerate the metabolism of Norestin, reducing its effectiveness. This is particularly important when Norestin is used for contraception, where reduced efficacy can result in unintended pregnancy; additional barrier contraception is recommended during and for some time after use of these interacting drugs.

Anticoagulants

Norestin may alter the anticoagulant effect of vitamin K antagonists such as warfarin; closer monitoring of coagulation parameters is advised when used together.

Ciclosporin

Norestin may inhibit the metabolism of ciclosporin, increasing its plasma levels and risk of toxicity; monitoring of ciclosporin levels and renal function is recommended.

Common side effects of Norestin include:

• Breakthrough bleeding or spotting between periods
• Breast tenderness or enlargement
• Headache
• Mood changes, including irritability or depression
• Weight changes (gain or, less commonly, loss)
• Acne or oily skin (Norestin has relatively more androgenic activity than some other progestins)
• Nausea, bloating, and fluid retention

Serious but uncommon effects include venous or arterial thromboembolic events - see Contraindications and Precautions and Warnings. Patients experiencing severe abdominal pain, chest pain, leg swelling, sudden severe headache, or visual disturbances while taking Norestin should seek medical attention promptly.

Pregnancy: Norestin is contraindicated in known or suspected pregnancy for its labeled gynecological and contraceptive indications; it should be discontinued immediately if pregnancy is suspected or confirmed. Norestin should never be used as a "test" for pregnancy. Consult a physician promptly if pregnancy occurs while taking Norestin.

Lactation: Progestin-only formulations of Norestin are generally considered compatible with breastfeeding by many guidelines when used for contraception, as they typically do not affect milk supply; however, Norestin should be used only if clearly needed and under a physician's guidance, since data on all indications and long-term infant effects remain limited.

• Assess for thromboembolic risk factors (e.g., smoking, obesity, immobility, personal/family history of clotting disorders) before starting Norestin, particularly for contraceptive-dose use; see Contraindications.
• Norestin should not be used to try to diagnose or "test for" pregnancy, as hormonal exposure early in pregnancy is a safety concern.
• Use Norestin with caution in patients with a history of depression, migraine, epilepsy, diabetes, hypertension, or cardiac or renal impairment, as these conditions may be aggravated by fluid retention or hormonal effects.
• Liver function should be monitored in patients with pre-existing hepatic disease; discontinue Norestin if jaundice or significant liver function abnormality develops.
• Breakthrough bleeding or spotting may occur, especially in the early cycles of Norestin use; if bleeding is heavy, persistent, or associated with pain, medical evaluation is warranted.
• Inform your physician of all other medications you take, due to potentially significant interactions with Norestin (see Interactions).

Overdose with Norestin is not generally life-threatening. Reported effects of excessive intake may include nausea, vomiting, breast tenderness, dizziness, and withdrawal bleeding. There is no specific antidote for Norestin overdose. If overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center; treatment is supportive and symptomatic based on the clinical presentation.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

No specific dose adjustment for Norestin is well established; use with caution and physician supervision, as fluid retention effects of progestins may be relevant in significant renal impairment.

Hepatic Impairment

Norestin is contraindicated in severe hepatic impairment or active liver tumors (see Contraindications); use with caution and close monitoring in mild-to-moderate hepatic disease.

Elderly

Norestin for gynecological indications is used in women of reproductive age; it is not generally indicated in postmenopausal women outside of hormone therapy regimens specifically formulated for that purpose.

Adolescents

Norestin may be used under specialist supervision for menstrual disorders once gynecological indications are confirmed; see Pediatric Uses.

Duration of Norestin treatment varies by indication: acute dysfunctional uterine bleeding is typically treated for 10 days; cyclic regimens (days 19-26) for prevention of recurrence, menorrhagia, or premenstrual syndrome are usually continued for several menstrual cycles as advised by the physician; endometriosis treatment is typically continued for 4 to 6 months; menstrual postponement uses Norestin short-term (a few days) around the expected period. Treatment duration should always be individualized and reviewed periodically by the prescribing physician.

Progestins (synthetic progestogens); 19-nortestosterone (estrane) derivative; female sex hormone. Norethisterone is a member of this drug class.

Norethisterone acts as a progesterone receptor agonist, converting proliferative endometrium to a secretory state and, at higher doses, suppressing the hypothalamic-pituitary-ovarian axis to inhibit ovulation. Due to its steroid structure, Norethisterone also has weak androgenic and estrogenic partial-agonist activity.

X (legacy FDA pregnancy category historically assigned to hormonal contraceptive/progestin products containing Norestin; confirm current labeling status with a physician)

Safety and efficacy of Norestin have not been established in children before puberty. In adolescents who have reached menarche, Norestin may be used under specialist gynecological supervision for conditions such as dysfunctional uterine bleeding, following the same evidence base as in adults, but treatment should be individualized and closely monitored given limited pediatric-specific data.